ME02417B - Kondenzovani derivati imidazola koji su korisni kao ido inhibitori - Google Patents

Kondenzovani derivati imidazola koji su korisni kao ido inhibitori

Info

Publication number
ME02417B
ME02417B MEP-2016-82A MEP201682A ME02417B ME 02417 B ME02417 B ME 02417B ME P201682 A MEP201682 A ME P201682A ME 02417 B ME02417 B ME 02417B
Authority
ME
Montenegro
Prior art keywords
imidazole derivatives
derivatives useful
ido inhibitors
fused imidazole
fused
Prior art date
Application number
MEP-2016-82A
Other languages
German (de)
English (en)
French (fr)
Unknown language (me)
Inventor
Mario Mautino
Sanjeev Kumar
Jesse Waldo
Firoz Jaipuri
Tanay Kesharwani
Xiaoxia Zhang
Original Assignee
Newlink Genetics Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Newlink Genetics Corp filed Critical Newlink Genetics Corp
Publication of ME02417B publication Critical patent/ME02417B/me

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4188—1,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Pulmonology (AREA)
  • Biotechnology (AREA)
  • Urology & Nephrology (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Dermatology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Hematology (AREA)
  • Neurosurgery (AREA)
  • Transplantation (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
MEP-2016-82A 2011-04-15 2012-04-12 Kondenzovani derivati imidazola koji su korisni kao ido inhibitori ME02417B (me)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161475788P 2011-04-15 2011-04-15
EP12715295.7A EP2697227B1 (en) 2011-04-15 2012-04-12 Fused imidazole derivatives useful as ido inhibitors
PCT/US2012/033245 WO2012142237A1 (en) 2011-04-15 2012-04-12 Fused imidazole derivatives useful as ido inhibitors

Publications (1)

Publication Number Publication Date
ME02417B true ME02417B (me) 2016-09-20

Family

ID=45976556

Family Applications (1)

Application Number Title Priority Date Filing Date
MEP-2016-82A ME02417B (me) 2011-04-15 2012-04-12 Kondenzovani derivati imidazola koji su korisni kao ido inhibitori

Country Status (30)

Country Link
US (5) US9260434B2 (Direct)
EP (3) EP2697227B1 (Direct)
JP (4) JP2014511876A (Direct)
KR (1) KR102164443B1 (Direct)
CN (2) CN103547579B (Direct)
AU (4) AU2012242871C1 (Direct)
BR (1) BR112013026494A2 (Direct)
CA (1) CA2833296C (Direct)
CL (1) CL2013002990A1 (Direct)
CO (1) CO6862146A2 (Direct)
CY (1) CY1117440T1 (Direct)
DK (2) DK2697227T3 (Direct)
ES (2) ES2660831T3 (Direct)
HK (1) HK1256355A1 (Direct)
HR (2) HRP20160369T1 (Direct)
HU (2) HUE027316T2 (Direct)
IL (3) IL228862A (Direct)
LT (1) LT3018132T (Direct)
ME (1) ME02417B (Direct)
MX (1) MX340442B (Direct)
NO (1) NO2694640T3 (Direct)
NZ (2) NZ708090A (Direct)
PE (2) PE20141124A1 (Direct)
PL (2) PL3018132T3 (Direct)
PT (1) PT3018132T (Direct)
RS (2) RS56992B1 (Direct)
RU (2) RU2017107026A (Direct)
SI (2) SI2697227T1 (Direct)
SM (1) SMT201600130B (Direct)
WO (1) WO2012142237A1 (Direct)

Families Citing this family (286)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NO2694640T3 (Direct) 2011-04-15 2018-03-17
JP6049712B2 (ja) 2011-07-08 2016-12-21 ザ ăƒŠăƒ‹ăƒăƒŒă‚·ăƒ†ă‚Ł ă‚Șブ ăƒŽăƒŒă‚č ă‚«ăƒ­ăƒ©ă‚€ăƒŠ ケット ăƒăƒŁăƒšăƒ« ăƒ’ăƒ«ïŒŽïœˆïœ…  ïŒŻïœ† ïŒźïœïœ’ïœ”ïœˆ ïŒŁïœïœ’ïœïœŒïœ‰ïœŽïœ ïŒĄïœ” ïŒŁïœˆïœïœïœ…ïœŒ  抗癌æČ»ç™‚ćŠăłç”»ćƒćŒ–äžŠăłă«éȘšéšœćźłæČ»ç™‚ăźăŸă‚ăźé‡‘ć±žăƒ“ă‚čホă‚čăƒ›ăƒăƒŒăƒˆăƒŠăƒŽçȒ歐
MX2015012028A (es) * 2013-03-14 2016-02-11 Curadev Pharma Private Ltd Inhibidores de la ruta de quinurenina.
RU2667509C2 (ru) * 2013-03-14 2018-09-21 ĐŃŒŃŽĐ»ĐžĐœĐș Đ”Đ¶ĐžĐœĐ”Ń‚ĐžĐșс ĐšĐŸŃ€ĐżĐŸŃ€Đ”ĐčŃˆĐžĐœ броцоĐșлОчДсĐșОД ŃĐŸĐ”ĐŽĐžĐœĐ”ĐœĐžŃ ĐČ ĐșачДстĐČĐ” ĐžĐœĐłĐžĐ±ĐžŃ‚ĐŸŃ€ĐŸĐČ ĐžĐŒĐŒŃƒĐœĐŸŃŃƒĐżŃ€Đ”ŃŃĐžĐž, ĐŸĐżĐŸŃŃ€Đ”ĐŽŃƒĐ”ĐŒĐŸĐč ĐŒĐ”Ń‚Đ°Đ±ĐŸĐ»ĐžĐ·ĐžŃ€ĐŸĐČĐ°ĐœĐžĐ”ĐŒ Ń‚Ń€ĐžĐżŃ‚ĐŸŃ„Đ°ĐœĐ°
GB201311888D0 (en) 2013-07-03 2013-08-14 Glaxosmithkline Ip Dev Ltd Novel compounds
GB201311891D0 (en) 2013-07-03 2013-08-14 Glaxosmithkline Ip Dev Ltd Novel compound
CN103382187B (zh) * 2013-08-06 2015-06-03 äżĄćźžç”Ÿç‰©ćŒ»èŻïŒˆäžŠæ”·ïŒ‰æœ‰é™ć…Źćž 侀种3-æ°Ż-7(5)-æșŽè‹Żćč¶ćŒ‚æ¶ć”‘çš„ćˆæˆæ–čæł•
SI3466949T1 (sl) 2013-12-24 2021-03-31 Bristol-Myers Squibb Company Triciklična spojina kot sredstvo proti raku
US20180228907A1 (en) 2014-04-14 2018-08-16 Arvinas, Inc. Cereblon ligands and bifunctional compounds comprising the same
SG10201810507WA (en) 2014-06-06 2018-12-28 Bristol Myers Squibb Co Antibodies against glucocorticoid-induced tumor necrosis factor receptor (gitr) and uses thereof
ES2751602T3 (es) 2014-09-05 2020-04-01 Merck Patent Gmbh Compuestos diaza y triaza tricĂ­clicos sustituidos con (1-fluoro-ciclohex-1-il)-etilo como antagonistas de la indol-amina-2,3-dioxigenasa (ido) para el tratamiento del cĂĄncer
GB201417369D0 (en) * 2014-10-01 2014-11-12 Redx Pharma Ltd Compounds
GB201418300D0 (en) * 2014-10-15 2014-11-26 Redx Pharma Ltd Compounds
DK3215518T3 (da) 2014-10-29 2021-05-25 Bicyclerd Ltd Bicykliske peptidligander, der er specifikke for mt1-mmp
HUE050596T2 (hu) 2014-11-21 2020-12-28 Bristol Myers Squibb Co Antitestek CD73 ellen Ă©s azok felhasznĂĄlĂĄsai
US10525035B2 (en) 2014-12-18 2020-01-07 Lankenau Institute For Medical Research Methods and compositions for the treatment of retinopathy and other ocular diseases
AR103232A1 (es) 2014-12-22 2017-04-26 Bristol Myers Squibb Co ANTAGONISTAS DE TGFbR
MX389267B (es) 2014-12-23 2025-03-20 Bristol Myers Squibb Co Anticuerpos contra el inmunorreceptor de células t con dominios de inmunoglobulina y de porción inhibidora con base en tirosina del inmumorreceptor (tigit).
WO2016127052A1 (en) 2015-02-05 2016-08-11 Bristol-Myers Squibb Company Cxcl11 and smica as predictive biomarkers for efficacy of anti-ctla4 immunotherapy
CN105884828A (zh) * 2015-02-16 2016-08-24 䞊攷èżȘèŻșćŒ»èŻç§‘æŠ€æœ‰é™ć…Źćž ć€šçŽŻćŒ–ćˆç‰©ă€ć…¶èŻç‰©ç»„ćˆç‰©ćŠćș”甚
PE20171789A1 (es) 2015-03-02 2017-12-28 Bristol Myers Squibb Co Inhibidores del factor beta de crecimiento de transformacion (tgf-beta)
CA2981584A1 (en) 2015-04-03 2016-10-06 Bristol-Myers Squibb Company Inhibitors of indoleamine 2,3-dioxygenase for the treatment of cancer
WO2016162505A1 (en) 2015-04-08 2016-10-13 F-Star Biotechnology Limited Her2 binding agent therapies
EP3280715B1 (en) * 2015-04-10 2020-11-25 Beigene, Ltd. NOVEL 5 OR 8-SUBSTITUTED IMIDAZO [1, 5-a]PYRIDINES AS INDOLEAMINE AND/OR TRYPTOPHANE 2, 3-DIOXYGENASES
CN108026098B (zh) * 2015-04-12 2019-09-03 æ­ć·žè‹±ćˆ›ćŒ»èŻç§‘æŠ€æœ‰é™ć…Źćž 䜜äžșido撌tdoæŠ‘ćˆ¶ć‰‚çš„æ‚çŽŻćŒ–ćˆç‰©
CA2980460A1 (en) 2015-04-13 2016-10-20 Five Prime Therapeutics, Inc. Combination therapy for cancer
EP3287461B1 (en) * 2015-04-21 2020-03-18 Jiangsu Hengrui Medicine Co., Ltd. Imidazo isoindole derivative, preparation method therefor and medical use thereof
ES2815683T3 (es) 2015-05-11 2021-03-30 Bristol Myers Squibb Co Compuestos tricĂ­clicos como agentes antineoplĂĄsicos
US10174024B2 (en) 2015-05-12 2019-01-08 Bristol-Myers Squibb Company 5H-pyrido[3,2-B]indole compounds as anticancer agents
US9725449B2 (en) 2015-05-12 2017-08-08 Bristol-Myers Squibb Company Tricyclic compounds as anticancer agents
CA2987410A1 (en) 2015-05-29 2016-12-08 Bristol-Myers Squibb Company Antibodies against ox40 and uses thereof
GB2548542A (en) * 2015-06-16 2017-09-27 Redx Pharma Plc Compounds
CN106256830B (zh) * 2015-06-18 2019-03-08 æˆéƒœæ”·ćˆ›èŻäžšæœ‰é™ć…Źćž äž€ç§æ°˜ä»Łçš„idoæŠ‘ćˆ¶ć‰‚ćŠć…¶ćˆ¶ć€‡æ–čæł•ć’Œç”šé€”
MX2017016502A (es) 2015-06-29 2018-03-12 Univ Rockefeller Anticuerpos contra cd40 con actividad agonista mejorada.
CN105037371A (zh) * 2015-06-30 2015-11-11 è„żćŽć€§ć­Š äž€ç§æ°˜ä»Łçš„ćČ據èƒș-2,3-ćŒćŠ æ°§é…¶æŠ‘ćˆ¶ć‰‚
GB201511790D0 (en) 2015-07-06 2015-08-19 Iomet Pharma Ltd Pharmaceutical compound
BR112018000903A2 (pt) 2015-07-16 2018-09-11 Biokine Therapeutics Ltd. composiçÔes e métodos para o tratamento de cùncer
EP3324958B1 (en) 2015-07-24 2021-07-28 Lumos Pharma, Inc. Salts and prodrugs of 1-methyl-d-tryptophan
US10399987B2 (en) 2015-07-28 2019-09-03 Bristol-Myer Squibb Company TGF beta receptor antagonists
EP3337476A4 (en) 2015-08-19 2019-09-04 Arvinas, Inc. Compounds and methods for the targeted degradation of bromodomain-containing proteins
KR20180042370A (ko) 2015-08-25 2018-04-25 ëžŒëŠŹìŠ€í†š-마읎얎슀 슀큅 컎퍌니 Tgf ëȠ타 수용ìČŽ êžží•­ì œ
CN106478634B (zh) * 2015-09-01 2020-05-22 ć°šćŽćŒ»èŻç§‘æŠ€(æ±Ÿè„ż)æœ‰é™ć…Źćž 皠搈ć’Șć”‘ćŒ–ćˆç‰©ă€ć…¶ćˆ¶ć€‡æ–čæł•ă€èŻç‰©ç»„ćˆç‰©ć’Œç”šé€”
US10308647B2 (en) 2015-10-29 2019-06-04 Scifluor Life Sciences, Inc. Fused imidazole derivatives as IDO/TDO inhibitors
MX2018005517A (es) 2015-11-02 2018-11-09 Five Prime Therapeutics Inc Polipeptidos del dominio extracelular de cd80 y su uso en el tratamiento del cancer.
HK1254241A1 (zh) * 2015-11-09 2019-07-12 F. Hoffmann-La Roche Ag ç”šæ–Œé‰Žćźšido1撌/或tdoè°ƒèŠ‚ć‰‚çš„ç­›é€‰æ”‹ćźšæł•
EP3377532B1 (en) 2015-11-19 2022-07-27 Bristol-Myers Squibb Company Antibodies against glucocorticoid-induced tumor necrosis factor receptor (gitr) and uses thereof
CN116327924A (zh) 2015-11-23 2023-06-27 戊瑞æČ»ç–—æœ‰é™ć…Źćž 甹äșŽç™Œç—‡æČ»ç–—çš„ć•ç‹Źfgfr2æŠ‘ćˆ¶ć‰‚æˆ–äžŽć…ç–«ćˆșæż€ć‰‚çš„ç»„ćˆ
US10450318B2 (en) 2015-12-15 2019-10-22 Bristol-Myers Squibb Company CXCR4 receptor antagonists
CN110072864B (zh) * 2015-12-24 2022-05-27 ćŸșć› æł°ć…‹ć…Źćž Tdo2æŠ‘ćˆ¶ć‰‚
CN107056785B (zh) * 2016-01-02 2021-06-22 æ­ć·žè‹±ćˆ›ćŒ»èŻç§‘æŠ€æœ‰é™ć…Źćž 䜜äžșido撌tdoæŠ‘ćˆ¶ć‰‚çš„æ‚çŽŻćŒ–ćˆç‰©
SG11201806480UA (en) 2016-02-02 2018-08-30 Emcure Pharmaceuticals Ltd Derivatives of pyrroloimidazole or analogues thereof which are useful for the treatment of inter alia cancer
JP7066186B2 (ja) 2016-02-19 2022-05-13 ケンă‚čăƒ†ă‚Łăƒăƒ„ ăƒŠă‚·ăƒ§ăƒŠăƒ« ăƒ‰ă‚„ ラ ă‚”ăƒłăƒ† ス ăƒ‰ă‚„ ラ ăƒ«ă‚·ă‚§ăƒ«ă‚·ăƒ„ ăƒĄăƒ‡ă‚Łă‚«ăƒ« è‚„æș€ăźć‡ŠçœźăźăŸă‚ăźæ–čæł•ćŠăłćŒ»è–Źç”„æˆç‰©
CN108884104B (zh) * 2016-02-19 2021-01-15 æ­Łć€§ć€©æ™ŽèŻäžšé›†ć›ąè‚Ąä»œæœ‰é™ć…Źćž 䜜äžșć…ç–«è°ƒèŠ‚ć‰‚çš„äž‰ćč¶çŽŻćŒ–ćˆç‰©
US10487088B2 (en) 2016-02-19 2019-11-26 Chia Tai Tianqing Pharmaceutical Group Co., Ltd. Tricyclic compound serving as immunomodulator
WO2017149469A1 (en) 2016-03-03 2017-09-08 Emcure Pharmaceuticals Limited Heterocyclic compounds useful as ido and/or tdo modulators
JP2019514844A (ja) 2016-03-04 2019-06-06 ブăƒȘă‚čăƒˆăƒ«âˆ’ăƒžă‚€ăƒ€ăƒŒă‚ș ă‚čă‚Żă‚€ăƒ– ă‚«ăƒłăƒ‘ăƒ‹ăƒŒïŒąïœ’ïœ‰ïœ“ïœ”ïœïœŒâˆ’ïŒ­ïœ™ïœ…ïœ’ïœ“ ïŒłïœ‘ïœ•ïœ‰ïœ‚ïœ‚ ïŒŁïœïœïœïœïœŽïœ™ æŠ—ïœƒïœ„ïŒ—ïŒ“æŠ—äœ“ă‚’ç”šă„ăŸäœ”ç”šç™‚æł•
CN105732643A (zh) * 2016-04-18 2016-07-06 è‹ć·žć€§ć­Š äž€ç§ć¶è”ç‰©ă€ć…¶ćˆ¶ć€‡æ–čæł•ćŠćœšćˆ¶ć€‡idoé…¶æŠ‘ćˆ¶ć‰‚ć’Œéžç”Ÿäœ“æŠ—ç‚ŽèŻç‰©äž­çš„ćș”甚
US12297266B2 (en) 2016-04-18 2025-05-13 Celldex Therapeutics, Inc. Agonistic antibodies that bind human CD40 and uses thereof
CN107312005B (zh) * 2016-04-27 2021-12-17 äžŠæ”·çż°æŁźç”Ÿç‰©ćŒ»èŻç§‘æŠ€æœ‰é™ć…Źćž ć…·æœ‰ido/tdoæŠ‘ćˆ¶æŽ»æ€§çš„çš ćˆć’Șć”‘èĄç”Ÿç‰©ćŠć…¶ćˆ¶ć€‡æ–čæł•ć’Œćș”甚
KR20190003685A (ko) 2016-05-04 2019-01-09 ëžŒëŠŹìŠ€í†š-마읎얎슀 슀큅 컎퍌니 ìžëŒì•„ëŻŒ 2,3-디옄시êČŒë‚˜ì œì˜ 얔제제 및 귞의 ì‚Źìš© ë°©ëȕ
US10544099B2 (en) 2016-05-04 2020-01-28 Bristol-Myers Squibb Company Inhibitors of indoleamine 2,3-dioxygenase and methods of their use
WO2017192813A1 (en) 2016-05-04 2017-11-09 Bristol-Myers Squibb Company Inhibitors of indoleamine 2,3-dioxygenase and methods of their use
JP2019516682A (ja) 2016-05-04 2019-06-20 ブăƒȘă‚čăƒˆăƒ«âˆ’ăƒžă‚€ăƒ€ăƒŒă‚ș ă‚čă‚Żă‚€ăƒ– ă‚«ăƒłăƒ‘ăƒ‹ăƒŒïŒąïœ’ïœ‰ïœ“ïœ”ïœïœŒâˆ’ïŒ­ïœ™ïœ…ïœ’ïœ“ ïŒłïœ‘ïœ•ïœ‰ïœ‚ïœ‚ ïŒŁïœïœïœïœïœŽïœ™ ă‚€ăƒłăƒ‰ăƒŒăƒ«ă‚ąăƒŸăƒłïŒ’ïŒŒïŒ“âˆ’ă‚žă‚Șă‚­ă‚·ă‚ČăƒŠăƒŒă‚Œé˜»ćźłć‰€ăŠă‚ˆăłăăźäœżç”šæ–čæł•
EP3452452A4 (en) 2016-05-04 2019-10-30 Bristol-Myers Squibb Company INHIBITORS OF INDOLEAMINE-2,3-DIOXYGENASE AND METHOD FOR THEIR USE
EP3454856B1 (en) 2016-05-10 2024-09-11 C4 Therapeutics, Inc. Heterocyclic degronimers for target protein degradation
CN109641874A (zh) 2016-05-10 2019-04-16 C4ćŒ»èŻć…Źćž 甹äșŽé¶è›‹ç™œé™è§Łçš„c3-çąłèżžæŽ„çš„æˆŠäșŒé…°äșšèƒșé™è§Łć†łćźšć­äœ“
WO2017197051A1 (en) 2016-05-10 2017-11-16 C4 Therapeutics, Inc. Amine-linked c3-glutarimide degronimers for target protein degradation
ES2990061T3 (es) 2016-05-10 2024-11-28 C4 Therapeutics Inc DegronĂ­meros espirocĂ­clicos para la degradaciĂłn de proteĂ­nas diana
CN107383012B (zh) * 2016-05-16 2021-09-28 éČć—ćˆ¶èŻé›†ć›ąè‚Ąä»œæœ‰é™ć…Źćž 搫äșŒçŽŻçš„ć’Șć”‘é†‡èĄç”Ÿç‰©
CN107556316B (zh) * 2016-06-30 2021-11-12 éČć—ćˆ¶èŻé›†ć›ąè‚Ąä»œæœ‰é™ć…Źćž ć«æĄ„çŽŻçš„ć’Șć”‘èĄç”Ÿç‰©
WO2017198159A1 (zh) * 2016-05-16 2017-11-23 éČć—ćˆ¶èŻé›†ć›ąè‚Ąä»œæœ‰é™ć…Źćž ć«æĄ„çŽŻçš„ć’Șć”‘èĄç”Ÿç‰©
CN105902542A (zh) * 2016-05-16 2016-08-31 ćŒ é˜ł äž€ç§ć¶è”ç‰©ćœšćˆ¶ć€‡æČ»ç–—ćżƒèĄ€çźĄç–Ÿç—…èŻç‰©äž­çš„ćș”甚
CN106957318B (zh) * 2016-05-19 2019-12-10 äž­ć›œç§‘ć­Šé™ąäžŠæ”·æœ‰æœșćŒ–ć­Šç ”ç©¶æ‰€ çš ćˆć€šçŽŻćČć“šć•‰ćŒ–ćˆç‰©ă€ć…¶ćˆ¶ć€‡æ–čæł•ă€èŻç‰©ç»„ćˆç‰©ćŠćș”甚
US11246877B2 (en) 2016-05-20 2022-02-15 The University Of Chicago Nanoparticles for chemotherapy, targeted therapy, photodynamic therapy, immunotherapy, and any combination thereof
AR108586A1 (es) 2016-06-10 2018-09-05 Lilly Co Eli Compuestos de 2,3-dihidro-1h-indol
CN107488179B (zh) * 2016-06-11 2024-06-07 éČć—ćˆ¶èŻé›†ć›ąè‚Ąä»œæœ‰é™ć…Źćž ć«æĄ„çŽŻçš„ć’Șć”‘é†‡èĄç”Ÿç‰©
CN107556315B (zh) * 2016-06-30 2021-08-31 éČć—ćˆ¶èŻé›†ć›ąè‚Ąä»œæœ‰é™ć…Źćž ć«ć››ć…ƒçŽŻçš„ć’Șć”‘èĄç”Ÿç‰©
US20190248893A1 (en) 2016-07-14 2019-08-15 Bristol-Myers Squibb Company Antibodies against tim3 and uses thereof
WO2018017633A1 (en) 2016-07-21 2018-01-25 Bristol-Myers Squibb Company TGF Beta RECEPTOR ANTAGONISTS
CN107663159A (zh) * 2016-07-29 2018-02-06 䞊攷èżȘèŻșćŒ»èŻç§‘æŠ€æœ‰é™ć…Źćž ć€šçŽŻćŒ–ćˆç‰©ă€ć…¶èŻç‰©ç»„ćˆç‰©ćŠćș”甚
WO2018028491A1 (zh) * 2016-08-09 2018-02-15 è‹ć·žć›œćŒĄćŒ»èŻç§‘æŠ€æœ‰é™ć…Źćž ćČ據èƒș23-ćŒćŠ æ°§é…¶æŠ‘ćˆ¶ć‰‚ćŠć…¶ćœšèŻć­Šäž­çš„ç”šé€”
CN109843322A (zh) 2016-08-26 2019-06-04 ç™Ÿæ—¶çŸŽæ–œèŽ”ćźć…Źćž ćČ據èƒș2,3-ćŒćŠ æ°§é…¶çš„æŠ‘ćˆ¶ć‰‚ćŠć…¶äœżç”šæ–čæł•
WO2018045966A1 (zh) * 2016-09-12 2018-03-15 ćčżć·žćż…莝ç‰čćŒ»èŻæŠ€æœŻæœ‰é™ć…Źćž 搫ć’Șć”‘çš ćˆäž‰çŽŻç±»ćŒ–ćˆç‰©ćŠć…¶ćș”甚
TW201815766A (zh) 2016-09-22 2018-05-01 çŸŽć•†æ™źé›·èŸ›è‚Żć…Źćž ç”šæ–Œïœ‰ïœ„ïœćŠïœ”ïœ„ïœèȘżçŻ€äč‹ćŒ–ćˆç‰©ćŠæ–čæł•ä»„ćŠć…¶é©æ‡‰ç—‡
WO2018054365A1 (en) 2016-09-24 2018-03-29 Beigene, Ltd. NOVEL 5 or 8-SUBSTITUTED IMIDAZO [1, 5-a] PYRIDINES AS SELECTIVE INHIBITORS OF INDOLEAMINE AND/OR TRYPTOPHANE 2, 3-DIOXYGENASES
MA46649A (fr) 2016-10-13 2019-08-21 Juno Therapeutics Inc Méthodes et compositions d'immunothérapie impliquant des modulateurs de la voie métabolique du tryptophane
TW201815417A (zh) * 2016-10-21 2018-05-01 è˜‡ć·žç››èżȘäșžç”Ÿç‰©é†«è—„æœ‰é™ć…Źćž ïŒ°ïœ„ïŒïŒ‘æŠ—é«”èˆ‡ïœ‰ïœ„ïœæŠ‘ćˆ¶ćŠ‘èŻćˆćœšèŁœć‚™æŠ—è…«ç˜€çš„è—„ç‰©äž­çš„ç”šé€”
WO2018072742A1 (zh) * 2016-10-21 2018-04-26 æ±Ÿè‹æ’ç‘žćŒ»èŻè‚Ąä»œæœ‰é™ć…Źćž 侀种ć’Ș攑ćč¶ćŒ‚ćČć“šç±»èĄç”Ÿç‰©çš„æžžçŠ»çą±çš„ç»“æ™¶ćœąćŒćŠć…¶ćˆ¶ć€‡æ–čæł•
EP3535243B1 (en) 2016-11-04 2021-12-15 Auckland Uniservices Limited Substituted 9h-xanthen-9-one, 9h-thioxanthen-9-one and acridin-9(10h)-one derivatives and related compounds csf-1r inhibitors for the treatment of cancer
CN106474468B (zh) * 2016-11-23 2020-03-27 äž­ć›œćŒ»ć­Šç§‘ć­Šé™ąćŒ»ć­Šç”Ÿç‰©ć­Šç ”ç©¶æ‰€ äž€ç§ć€ćˆäœć‰‚ă€ć«èŻ„ć€ćˆäœć‰‚çš„ç–«è‹—ćŠç–«è‹—çš„ćˆ¶ć€‡æ–čæł•
WO2018106579A1 (en) * 2016-12-06 2018-06-14 Albert Einstein College Of Medicine, Inc. Drug targeting of human indoleamine 2,3-dioxygenase
US10604529B2 (en) 2016-12-20 2020-03-31 Shenzhen Chipscreen Biosciences Co., Ltd. Fused imidazole compound having indoleamine 2,3-dioxygenase inhibitory activity
CN114989205A (zh) 2016-12-22 2022-09-02 ćĄé‡ŒćĄžæ‹‰ç”Ÿç‰©ç§‘ć­Šè‚Ąä»œć…Źćž 甹äșŽæŠ‘ćˆ¶çČŸæ°šé…žé…¶æŽ»æ€§çš„ç»„ćˆç‰©ć’Œæ–čæł•
CN108239091B (zh) * 2016-12-26 2021-08-13 äž­ć›œćŒ»ć­Šç§‘ć­Šé™ąèŻç‰©ç ”ç©¶æ‰€ 1-环深ćŸș-2-(5H-ć’Ș攑[5,1-a]ćŒ‚ćČ據)äč™ćŸș-1-é…źçš„æ‹†ćˆ†
US10961239B2 (en) 2017-01-05 2021-03-30 Bristol-Myers Squibb Company TGF beta receptor antagonists
CA3047002A1 (en) 2017-01-17 2018-07-26 Board Of Regents, The University Of Texas System Compounds useful as inhibitors of indoleamine 2,3-dioxygenase and/or tryptophan dioxygenase
WO2018175954A1 (en) 2017-03-23 2018-09-27 F. Hoffmann-La Roche Ag Synthesis of imidazo[5,1-a]isoindole derivative useful as ido inhibitors
CN110709420A (zh) 2017-03-31 2020-01-17 戊瑞æČ»ç–—æœ‰é™ć…Źćž äœżç”šæŠ—gitræŠ—äœ“çš„ç™Œç—‡ç»„ćˆç–—æł•
TWI788340B (zh) 2017-04-07 2023-01-01 çŸŽć•†ćż…æČ»ćŠ„çŸŽé›…ćČè°·æŻ”ć…Źćž 抗icosäżƒæ•ˆćŠ‘æŠ—é«”ćŠć…¶ç”šé€”
CA3059939A1 (en) 2017-04-21 2018-10-25 Kyn Therapeutics Indole ahr inhibitors and uses thereof
WO2018201014A1 (en) 2017-04-28 2018-11-01 Five Prime Therapeutics, Inc. Methods of treatment with cd80 extracellular domain polypeptides
WO2018209049A1 (en) 2017-05-12 2018-11-15 Bristol-Myers Squibb Company Inhibitors of indoleamine 2,3-dioxygenase and methods of their use
CN107176956B (zh) * 2017-05-31 2019-11-12 æˆéƒœæ”·ćšé”èŻäžšæœ‰é™ć…Źćž 侀种idoæŠ‘ćˆ¶ć‰‚ćŒ–ćˆç‰©ă€èŻç”šç»„ćˆç‰©ă€ç”šé€”
EP3641762A4 (en) 2017-06-20 2021-03-10 C4 Therapeutics, Inc. N / O-LINKED DEGRONES AND DEGRONIMERS FOR PROTEIN DEGRADATION
WO2019005559A1 (en) 2017-06-28 2019-01-03 Genentech, Inc. INHIBITORS OF TDO2 AND IDO1
US11827639B2 (en) 2017-06-28 2023-11-28 Genentech, Inc. TDO2 and IDO1 inhibitors
MX391848B (es) 2017-06-30 2025-03-19 Bristol Myers Squibb Co Formas amorfas y cristalinas de inhibidores de indolamina 2,3-dioxigenasa (ido)
ES2932354T3 (es) 2017-07-28 2023-01-18 Bristol Myers Squibb Co DinucleĂłtidos cĂ­clicos como agentes anticĂĄncer
US11826426B2 (en) 2017-08-02 2023-11-28 The University Of Chicago Nanoscale metal-organic layers and metal-organic nanoplates for x-ray induced photodynamic therapy, radiotherapy, radiodynamic therapy, chemotherapy, immunotherapy, and any combination thereof
JP7670481B2 (ja) 2017-08-04 2025-04-30 ăƒă‚€ă‚čă‚Żăƒ«ăƒ†ă‚Żă‚č・ăƒȘミテッド ïŒŁïœ„ïŒ‘ïŒ“ïŒ—ă«ćŻŸă—ăŠç‰č異的ăȘäșŒç’°ćŒăƒšăƒ—ăƒăƒ‰ăƒȘガンド
CN109983019B (zh) * 2017-08-08 2021-12-21 æ±Ÿè‹æ’ç‘žćŒ»èŻè‚Ąä»œæœ‰é™ć…Źćž 侀种ć’Ș攑ćč¶ćŒ‚ćČć“šç±»èĄç”Ÿç‰©çš„ćˆ¶ć€‡æ–čæł•
CN109384791B (zh) * 2017-08-09 2020-09-11 æ±Ÿè‹æ’ç‘žćŒ»èŻè‚Ąä»œæœ‰é™ć…Źćž 侀种ć’Ș攑ćč¶ćŒ‚ćČć“šç±»èĄç”Ÿç‰©æžžçŠ»çą±çš„æ™¶ćž‹ćŠć…¶ćˆ¶ć€‡æ–čæł•
EP3668496A4 (en) 2017-08-17 2021-07-14 Ikena Oncology, Inc. AHR INHIBITORS AND THEIR USES
JP7110325B2 (ja) 2017-08-17 2022-08-01 ă‚€ăƒ‰ăƒŒă‚·ă‚ą ăƒ•ă‚ĄăƒŒăƒžă‚·ăƒ„ăƒŒăƒ†ă‚Łă‚«ăƒ«ă‚ș ăƒȘミテッド ă‚€ăƒłăƒ‰ăƒŒăƒ«ă‚ąăƒŸăƒł ïŒ’ïŒŒïŒ“ïŒă‚žă‚Șă‚­ă‚·ă‚ČăƒŠăƒŒă‚ŒćŠăłïŒćˆăŻăƒˆăƒȘプトファン ïŒ’ïŒŒïŒ“ïŒă‚žă‚Șă‚­ă‚·ă‚ČăƒŠăƒŒă‚Œăźé˜»ćźłć‰€
WO2019034139A1 (zh) * 2017-08-18 2019-02-21 æ­Łć€§ć€©æ™ŽèŻäžšé›†ć›ąè‚Ąä»œæœ‰é™ć…Źćž 侀种侉ćč¶çŽŻćŒ–ćˆç‰©çš„ç»“æ™¶
CN111051305A (zh) * 2017-08-22 2020-04-21 ć‰ćˆ©ćŸ·ç§‘ć­Šć…Źćž æČ»ç–—æ€§æ‚çŽŻćŒ–ćˆç‰©
EP3676277A1 (en) 2017-08-31 2020-07-08 Bristol-Myers Squibb Company Cyclic dinucleotides as anticancer agents
WO2019046498A1 (en) 2017-08-31 2019-03-07 Bristol-Myers Squibb Company CYCLIC DINUCLEOTIDES AS ANTICANCER AGENTS
EP3676279B1 (en) 2017-08-31 2021-12-01 Bristol-Myers Squibb Company Cyclic dinucleotides as anticancer agents
CN107501272B (zh) * 2017-09-05 2020-03-31 äž­ć›œèŻç§‘ć€§ć­Š ć’Ș攑ćč¶ćŒ‚ćČć“šç±»ido1æŠ‘ćˆ¶ć‰‚ă€ć…¶ćˆ¶ć€‡æ–čæł•ćŠćș”甚
ES2935729T3 (es) 2017-09-14 2023-03-09 Lankenau Inst Medical Res MĂ©todos y composiciones para el tratamiento del cĂĄncer
WO2019060693A1 (en) 2017-09-22 2019-03-28 Kymera Therapeutics, Inc. CRBN LIGANDS AND USES THEREOF
AU2018338314B2 (en) 2017-09-22 2024-12-12 Kymera Therapeutics, Inc Protein degraders and uses thereof
WO2019074824A1 (en) 2017-10-09 2019-04-18 Bristol-Myers Squibb Company INDOLEAMINE 2,3-DIOXYGENASE INHIBITORS AND METHODS OF USE
WO2019074822A1 (en) 2017-10-09 2019-04-18 Bristol-Myers Squibb Company INDOLEAMINE 2,3-DIOXYGENASE INHIBITORS AND METHODS OF USE
WO2019074887A1 (en) 2017-10-10 2019-04-18 Bristol-Myers Squibb Company CYCLIC DINUCLEOTIDES AS ANTICANCER AGENTS
US11230601B2 (en) 2017-10-10 2022-01-25 Tilos Therapeutics, Inc. Methods of using anti-lap antibodies
JP7254821B2 (ja) 2017-10-16 2023-04-10 ブăƒȘă‚čăƒˆăƒ«ïŒăƒžă‚€ăƒ€ăƒŒă‚ș ă‚čă‚Żă‚€ăƒ– ă‚«ăƒłăƒ‘ăƒ‹ăƒŒ æŠ—ăŒă‚“ć‰€ăšă—ăŠăźç’°çŠ¶ă‚žăƒŒă‚ŻăƒŹă‚Șチド
JP7306634B2 (ja) 2017-10-19 2023-07-11 äž€èˆŹç€Ÿć›Łæł•äșșăƒ•ă‚Ąăƒ«ăƒžăƒăƒŹăƒŒăƒ—ăƒ­ă‚žă‚§ă‚Żăƒˆæ”ŻæŽæ©Ÿæ§‹ ïŒ©ïœ„ïœïŒïœ”ïœ„ïœé˜»ćźłć‰€
KR20200074214A (ko) 2017-11-01 2020-06-24 ëžŒëŠŹìŠ€í†š-마읎얎슀 슀큅 컎퍌니 암을 ìč˜ëŁŒí•˜ëŠ”데 ì‚Źìš©í•˜êž° 위한 멎역자ê·č 횚늄작용 항ìČŽ
EP3707138B1 (en) 2017-11-06 2022-07-13 Bristol-Myers Squibb Company Isofuranone compounds useful as hpk1 inhibitors
US11472788B2 (en) 2017-11-25 2022-10-18 Beigene, Ltd. Benzoimidazoles as selective inhibitors of indoleamine 2,3-dioxygenases
IL315310A (en) 2017-12-26 2024-10-01 Kymera Therapeutics Inc Irak degraders and uses thereof
CN111788227B (zh) 2017-12-27 2025-02-25 ç™Ÿæ—¶çŸŽæ–œèŽ”ćźć…Źćž 抗cd40æŠ—äœ“ćŠć…¶ç”šé€”
US11447449B2 (en) 2018-01-05 2022-09-20 Bristol-Myers Squibb Company Inhibitors of indoleamine 2,3-dioxygenase and methods of their use
EP3737675A4 (en) 2018-01-12 2022-01-05 Kymera Therapeutics, Inc. Crbn ligands and uses thereof
EP3737700A1 (en) 2018-01-12 2020-11-18 Bristol-Myers Squibb Company Antibodies against tim3 and uses thereof
EP3737666A4 (en) 2018-01-12 2022-01-05 Kymera Therapeutics, Inc. PROTEIN DEGRADATION AGENTS AND ASSOCIATED USES
US20200405696A1 (en) 2018-01-15 2020-12-31 Idorsia Pharmaceuticals Ltd Inhibitors of indoleamine 2,3-dioxygenase and/or tryptophan 2,3-dioxygenase
WO2019141095A1 (zh) * 2018-01-19 2019-07-25 ć››ć·ç§‘äŒŠćšæł°ç”Ÿç‰©ćŒ»èŻè‚Ąä»œæœ‰é™ć…Źćž è„’ç±»ć’Œèƒç±»èĄç”Ÿç‰©ă€ć…¶ćˆ¶ć€‡æ–čæł•ćŠć…¶ćœšćŒ»èŻäžŠçš„ćș”甚
EP4616913A3 (en) 2018-01-29 2025-12-10 Merck Patent GmbH Gcn2 inhibitors and uses thereof
CN111867581B (zh) 2018-01-29 2023-12-26 é»˜ć…‹äž“ćˆ©è‚Ąä»œæœ‰é™ć…Źćž Gcn2æŠ‘ćˆ¶ć‰‚ćŠć…¶ç”šé€”
US10519187B2 (en) 2018-02-13 2019-12-31 Bristol-Myers Squibb Company Cyclic dinucleotides as anticancer agents
CA3091775A1 (en) 2018-02-23 2019-08-29 Bicycletx Limited Multimeric bicyclic peptide ligands
JP7250808B2 (ja) 2018-03-08 2023-04-03 ブăƒȘă‚čăƒˆăƒ«ïŒăƒžă‚€ăƒ€ăƒŒă‚ș ă‚čă‚Żă‚€ăƒ– ă‚«ăƒłăƒ‘ăƒ‹ăƒŒ æŠ—ăŒă‚“ć‰€ăšă—ăŠăźç’°çŠ¶ă‚žăƒŒă‚ŻăƒŹă‚Șチド
CN112119072A (zh) 2018-03-20 2020-12-22 æ™źèŽ±ćžŒç§‘ć…Źćž 甹äșŽido撌tdoè°ƒèŠ‚çš„ćŒ–ćˆç‰©ć’Œæ–čæł•ïŒŒä»„ćŠć…¶é€‚ćș”ç—‡
TW201945393A (zh) 2018-03-21 2019-12-01 çŸŽć•†æˆŠç‘žæČ»ç™‚æœ‰é™ć…Źćž ćœšé…žæ€§pHç”ćˆè‡łVISTAäč‹æŠ—é«”
US11242393B2 (en) 2018-03-23 2022-02-08 Bristol-Myers Squibb Company Antibodies against MICA and/or MICB and uses thereof
BR112020020826A2 (pt) 2018-04-12 2021-01-19 Bristol-Myers Squibb Company Terapia de combinação anticùncer com anticorpo antagonista de cd73 e anticorpo antagonista do eixo pd-1/pd-l1
CA3096546A1 (en) 2018-04-16 2019-10-24 Arrys Therapeutics, Inc. Ep4 inhibitors and use thereof
US12037323B2 (en) 2018-05-03 2024-07-16 Bristol-Myers Squibb Company Uracil derivatives as Mer-AXL inhibitors
US11180531B2 (en) 2018-06-22 2021-11-23 Bicycletx Limited Bicyclic peptide ligands specific for Nectin-4
HUE064531T2 (hu) 2018-06-27 2024-04-28 Bristol Myers Squibb Co SzubsztituĂĄlt naftiridinon vegyĂŒletek mint T-sejt aktivĂĄtorok
DK3814347T3 (da) 2018-06-27 2023-08-07 Bristol Myers Squibb Co Naphthyridinonforbindelse, der er nyttige som t-celleaktivatorer
EP3817748A4 (en) 2018-07-06 2022-08-24 Kymera Therapeutics, Inc. TRICYCLIC CRBN LIGANDS AND USES THEREOF
WO2020010227A1 (en) 2018-07-06 2020-01-09 Kymera Therapeutics, Inc. Protein degraders and uses thereof
TW202428604A (zh) 2018-07-09 2024-07-16 çŸŽć•†æˆŠç‘žæČ»ç™‚æœ‰é™ć…Źćž ç”ćˆè‡łilt4的抗體
US12091462B2 (en) 2018-07-11 2024-09-17 Five Prime Therapeutics, Inc. Antibodies binding to vista at acidic pH
EP3823604A4 (en) 2018-07-17 2022-03-16 Board of Regents, The University of Texas System COMPOUNDS AS INHIBITORS OF INDOLAMINE-2,3-DIOXYGENASE AND/OR TRYPTOPHANE DIOXYGENASE
WO2020023356A1 (en) 2018-07-23 2020-01-30 Bristol-Myers Squibb Company Inhibitors of indoleamine 2,3-dioxygenase and methods of their use
US12059420B2 (en) 2018-07-23 2024-08-13 Bristol-Myers Squibb Company Inhibitors of indoleamine 2,3-dioxygenase and methods of their use
US11253525B2 (en) 2018-08-29 2022-02-22 Bristol-Myers Squibb Company Inhibitors of indoleamine 2,3-dioxygenase and methods of their use
US10959986B2 (en) 2018-08-29 2021-03-30 Bristol-Myers Squibb Company Inhibitors of indoleamine 2,3-dioxygenase and methods of their use
WO2020051424A1 (en) 2018-09-07 2020-03-12 Pic Therapeutics Eif4e inhibitors and uses thereof
JP7455133B2 (ja) * 2018-09-27 2024-03-25 ă‚·ă‚§ăƒłăƒă‚§ăƒł チップă‚čクăƒȘăƒŒăƒł ăƒă‚€ă‚Șă‚”ă‚€ă‚šăƒłă‚·ă‚ș ă‚«ăƒłăƒ‘ăƒ‹ăƒŒă€ăƒȘミテッド ă‚€ăƒłăƒ‰ăƒŒăƒ«ă‚ąăƒŸăƒłïŒïŒ’ïŒŒïŒ“ïŒă‚žă‚Șă‚­ă‚·ă‚ČăƒŠăƒŒă‚Œé˜»ćźłæŽ»æ€§ă‚’æœ‰ă™ă‚‹ă‚­ăƒŽăƒ­ăƒłèȘ˜ć°Žäœ“
TW202035445A (zh) 2018-10-10 2020-10-01 çŸŽć•†ćžæŽ›æ–Żç™‚æł•è‚Ąä»œæœ‰é™ć…Źćž 抗lapæŠ—é«”èźŠç•°é«”ćŠć…¶ç”šé€”
NZ777032A (en) 2018-11-16 2024-07-26 Bristol Myers Squibb Co Anti-nkg2a antibodies and uses thereof
SG11202105424PA (en) 2018-11-30 2021-06-29 Kymera Therapeutics Inc Irak degraders and uses thereof
GB201820295D0 (en) 2018-12-13 2019-01-30 Bicyclerd Ltd Bicyclic peptide ligands specific for MT1-MMP
GB201820288D0 (en) 2018-12-13 2019-01-30 Bicycle Tx Ltd Bicycle peptide ligaands specific for MT1-MMP
GB201820325D0 (en) 2018-12-13 2019-01-30 Bicyclerd Ltd Bicyclic peptide ligands specific for psma
EP3670659A1 (en) 2018-12-20 2020-06-24 Abivax Biomarkers, and uses in treatment of viral infections, inflammations, or cancer
EP3897631A4 (en) 2018-12-20 2022-11-23 C4 Therapeutics, Inc. TARGETED PROTEIN BREAKDOWN
WO2020128526A1 (en) 2018-12-21 2020-06-25 Bicycletx Limited Bicyclic peptide ligands specific for pd-l1
JP7684947B2 (ja) 2019-03-19 2025-05-28 ăƒ•ăƒłăƒ€ă‚·ă‚Ș プăƒȘバダ ă‚€ăƒłă‚čăƒ†ă‚Łăƒˆă‚„ăƒˆ ディンベă‚čăƒ†ă‚Łă‚Źă‚·ă‚Ș ă‚Șăƒłă‚łăƒ­ă‚žă‚« デ バル スブロン 癌ぼæČ»ç™‚ăźăŸă‚ăźäœ”ç”šç™‚æł•
JP2022528887A (ja) 2019-04-02 2022-06-16 ăƒă‚€ă‚čă‚Żăƒ«ăƒ†ă‚Żă‚č・ăƒȘミテッド ăƒă‚€ă‚·ă‚Żăƒ«ăƒˆă‚­ă‚·ăƒłă‚łăƒłă‚žăƒ„ă‚ČăƒŒăƒˆăŠă‚ˆăłăăźäœżç”š
KR20220006139A (ko) 2019-04-05 2022-01-14 ìčŽìŽë©”띌 쎄띌퓚틱슀 ìžìœ”íŹë ˆìŽí‹°ë“œ Stat 분핎제 및 읎의 용도
WO2020231766A1 (en) 2019-05-13 2020-11-19 Bristol-Myers Squibb Company AGONISTS OF ROR GAMMAt
WO2020231713A1 (en) 2019-05-13 2020-11-19 Bristol-Myers Squibb Company AGONISTS OF ROR GAMMAt
CN114502540A (zh) 2019-05-31 2022-05-13 ćŒ»è‚Żçșłè‚żç˜€ć­Šć…Źćž TeadæŠ‘ćˆ¶ć‰‚ć’Œć…¶ç”šé€”
US12521438B2 (en) 2019-06-10 2026-01-13 Kymera Therapeutics, Inc. SMARCA degraders and uses thereof
CA3146406A1 (en) 2019-07-11 2021-01-14 Idorsia Pharmaceuticals Ltd Inhibitors of indoleamine 2,3-dioxygenase and/or tryptophan 2,3-dioxygenase
US20220306630A1 (en) 2019-08-06 2022-09-29 Bristol-Myers Squibb Company AGONISTS OF ROR GAMMAt
AR119821A1 (es) 2019-08-28 2022-01-12 Bristol Myers Squibb Co Compuestos de piridopirimidinonilo sustituidos Ăștiles como activadores de cĂ©lulas t
CA3150108A1 (en) 2019-09-13 2021-03-18 Neelu Kaila Hpk1 antagonists and uses thereof
PE20220566A1 (es) 2019-09-19 2022-04-13 Bristol Myers Squibb Co ANTICUERPOS DE UNION A VISTA A pH ACIDO
TWI836159B (zh) 2019-11-19 2024-03-21 çŸŽć•†ćż…æČ»ćŠ„çŸŽé›…ćČè°·æŻ”ć…Źćž ćŻäœœç‚șhelios蛋癜èłȘæŠ‘ćˆ¶ćŠ‘äč‹ćŒ–ćˆç‰©
US11591339B2 (en) 2019-11-26 2023-02-28 Ikena Oncology, Inc. Solid forms of (R)-N-(2-(5-fluoropyridin-3-yl)-8-isopropylpyrazolo[ 1,5-a][1,3,5]triazin-4-yl)-2,3,4,9-tetrahydro-1H-carbazol-3-amine maleate as aryl hydrocarbon receptor (AHR) inhibitors
MX2022006134A (es) 2019-11-26 2022-06-17 Bristol Myers Squibb Co Sales/cocristales de (r)-n-(4-clorofenil)-2-((1s,4s)-4-(6-fluoroqu inolin-4-il)ciclohexil)propanamida.
CN111333653A (zh) * 2019-12-16 2020-06-26 ć±±äžœć€§ć­Š 侀种icdèŻ±ćŻŒć‰‚-idoæŠ‘ćˆ¶ć‰‚çŒ€ćˆç‰©ćŠćˆ¶ć€‡æ–čæł•äžŽćș”甚
WO2021127283A2 (en) 2019-12-17 2021-06-24 Kymera Therapeutics, Inc. Irak degraders and uses thereof
JP2023509366A (ja) 2019-12-17 2023-03-08 ă‚«ă‚€ăƒĄăƒ© ă‚»ăƒ©ăƒ”ăƒ„ăƒŒăƒ†ă‚Łă‚Żă‚č ă‚€ăƒłă‚łăƒŒăƒăƒŹă‚€ăƒ†ăƒƒăƒ‰ ïŒ©ïœ’ïœïœ‹ćˆ†è§Łć‰€ăŠă‚ˆăłăă‚Œă‚‰ăźäœżç”š
EP4081513B1 (en) 2019-12-23 2024-11-20 Bristol-Myers Squibb Company Substituted quinolinonyl piperazine compounds useful as t cell activators
AU2020412698A1 (en) 2019-12-23 2022-08-18 Bristol-Myers Squibb Company Substituted piperazine derivatives useful as T cell activators
CA3163003A1 (en) 2019-12-23 2021-07-01 Upender Velaparthi Substituted heteroaryl compounds useful as t cell activators
PH12022551522A1 (en) 2019-12-23 2024-01-29 Kymera Therapeutics Inc Smarca degraders and uses thereof
CN114846007B (zh) 2019-12-23 2024-11-22 ç™Ÿæ—¶çŸŽæ–œèŽ”ćźć…Źćž ćŻç”šäœœtç»†èƒžæż€æŽ»ć‰‚çš„ç»ć–ä»Łçš„ć–č攑敉ćŸșćŒ–ćˆç‰©
AR120823A1 (es) 2019-12-23 2022-03-23 Bristol Myers Squibb Co Compuestos bicĂ­clicos sustituidos Ăștiles como activadores de cĂ©lulas t
CN115996950A (zh) 2020-01-06 2023-04-21 é«˜èŻšç”Ÿç‰©ćŒ»èŻ(éŠ™æžŻ)æœ‰é™ć…Źćž 抗tnfr2æŠ—äœ“ć’Œć…¶ç”šé€”
MX2022008421A (es) 2020-01-07 2022-09-23 Hifibio Hk Ltd Anticuerpo anti-galectina-9 y usos del mismo.
EP4090663A1 (en) 2020-01-15 2022-11-23 Blueprint Medicines Corporation Map4k1 inhibitors
EP4114529A1 (en) 2020-03-03 2023-01-11 PIC Therapeutics, Inc. Eif4e inhibitors and uses thereof
EP4118118A1 (en) 2020-03-09 2023-01-18 Bristol-Myers Squibb Company Antibodies to cd40 with enhanced agonist activity
PH12022552458A1 (en) 2020-03-19 2024-01-22 Kymera Therapeutics Inc Mdm2 degraders and uses thereof
TW202140441A (zh) 2020-03-23 2021-11-01 çŸŽć•†ćż…æČ»ćŠ„çŸŽé›…ćČè°·æŻ”ć…Źćž ç¶“ć–ä»Łäč‹ćŽæ°§ćŸș異ćČć“šć•‰ćŒ–ćˆç‰©
US20230272056A1 (en) 2020-04-09 2023-08-31 Merck Sharp & Dohme Llc Affinity matured anti-lap antibodies and uses thereof
WO2021231732A1 (en) 2020-05-15 2021-11-18 Bristol-Myers Squibb Company Antibodies to garp
TW202210483A (zh) 2020-06-03 2022-03-16 çŸŽć•†ć‡±éș„æ‹‰é†«ç™‚ć…Źćž Iraké™è§ŁćŠ‘äč‹ç”æ™¶ćž‹
US20230250110A1 (en) 2020-06-03 2023-08-10 Kymera Therapeutics, Inc. Deuterated irak degraders and uses thereof
CN111803635B (zh) * 2020-06-17 2023-03-14 äž­ć›œćŒ»ć­Šç§‘ć­Šé™ąćŸșçĄ€ćŒ»ć­Šç ”ç©¶æ‰€ ć°ćˆ†ć­æŠ‘ćˆ¶ć‰‚ćœšæČ»ç–—ć‘Œćžé“ç—…æŻ’æ€§è‚ș炎侊的ćș”甚
WO2021258010A1 (en) 2020-06-19 2021-12-23 Gossamer Bio Services, Inc. Oxime compounds useful as t cell activators
US11839659B2 (en) 2020-07-02 2023-12-12 Northwestern University Proteolysis-targeting chimeric molecules (PROTACs) that induce degradation of indoleamine 2,3-dioxygenase (IDO) protein
US11857535B2 (en) 2020-07-30 2024-01-02 Kymera Therapeutics, Inc. Methods of treating mutant lymphomas
MX2023001707A (es) 2020-08-10 2023-05-04 Shanghai Xunbaihui Biotechnology Co Ltd Composiciones y métodos para el tratamiento de enfermedades autoinmunes y cånceres por direccionamiento al miembro 8 de la superfamilia de inmunoglobulinas.
KR20230074721A (ko) 2020-08-17 2023-05-31 ë°”ìŽì‚ŹìŽíŽí‹°ì—‘ìŠ€ 멬믾티드 Nectin-4에 íŠč읎적읞 읎환 ìœ˜ì„ŹêČŒìŽíŠž 및 읎의 용도
AU2021360782A1 (en) 2020-10-14 2023-06-08 Five Prime Therapeutics, Inc. Anti-c-c chemokine receptor 8 (ccr8) antibodies and methods of use thereof
WO2022120353A1 (en) 2020-12-02 2022-06-09 Ikena Oncology, Inc. Tead inhibitors and uses thereof
KR20230131189A (ko) 2020-12-02 2023-09-12 읎쌀나 ì˜šìœœëĄœì§€, ìžìœ”íŹë ˆìŽí‹°ë“œ Tead 얔제제 및 읎의 용도
AU2021400725A1 (en) 2020-12-16 2023-08-03 Gossamer Bio Services, Inc. Compounds useful as t cell activators
MX2023007852A (es) 2020-12-30 2023-07-07 Kymera Therapeutics Inc Degradadores de cinasas asociadas al receptor de interleucina-1 (irak) y usos de los mismos.
US20250186539A2 (en) 2021-01-11 2025-06-12 Bicycletx Limited Methods for treating cancer
KR20230153387A (ko) 2021-02-02 2023-11-06 멬믾널 ë°”ìŽì˜€ì‚ŹìŽì–žì‹œìŠ€ 멬믾티드 Gpr84 êžží•­ì œ 및 읎의 용도
MX2023009059A (es) 2021-02-02 2023-09-15 Liminal Biosciences Ltd Antagonistas de gpr84 y usos de estos.
WO2022169921A1 (en) 2021-02-04 2022-08-11 Bristol-Myers Squibb Company Benzofuran compounds as sting agonists
JP2024506339A (ja) 2021-02-12 2024-02-13 ă‚šăƒ•ăƒ»ăƒ›ăƒ•ăƒžăƒłïŒăƒ©ăƒ»ăƒ­ă‚·ăƒ„ăƒ»ă‚ąă‚Żăƒă‚§ăƒłă‚Čă‚Œăƒ«ă‚·ăƒŁăƒ•ăƒˆ がんぼæČ»ç™‚ăźăŸă‚ăźäșŒç’°ćŒăƒ†ăƒˆăƒ©ăƒ’ăƒ‰ăƒ­ă‚ąă‚Œăƒ”ăƒłèȘ˜ć°Žäœ“
CN117120090A (zh) 2021-02-12 2023-11-24 æž—äŒŻćŁ«èšéĄżć…Źćž Hpk1æ‹źæŠ—ć‰‚ć’Œć…¶ç”šé€”
IL304905A (en) 2021-02-15 2023-10-01 Kymera Therapeutics Inc IRAK4 joints and their uses
WO2022174268A1 (en) 2021-02-15 2022-08-18 Kymera Therapeutics, Inc. Irak4 degraders and uses thereof
CN117295737A (zh) 2021-03-05 2023-12-26 æž—äŒŻćŁ«èšéĄżć…Źćž Hpk1æ‹źæŠ—ć‰‚ć’Œć…¶ç”šé€”
MX2023010371A (es) 2021-03-05 2024-02-12 Univ Basel Composiciones para el tratamiento de enfermedades o condiciones asociadas al veb.
EP4052705A1 (en) 2021-03-05 2022-09-07 UniversitÀt Basel Vizerektorat Forschung Compositions for the treatment of ebv associated diseases or conditions
JP2024510176A (ja) 2021-03-08 2024-03-06 ăƒ–ăƒ«ăƒŒăƒ—ăƒȘント ăƒĄăƒ‡ă‚Łă‚·ăƒłă‚ș ă‚łăƒŒăƒăƒŹă‚€ă‚·ăƒ§ăƒł ïŒ­ïœïœïŒ”ïœ‹ïŒ‘é˜»ćźłć‰€
WO2022197641A1 (en) 2021-03-15 2022-09-22 Rapt Therapeutics, Inc. 1h-pyrazolo[3,4-d]pyrimidin-6-yl-amine derivatives as hematopoietic progenitor kinase 1 (hpk1) modulators and/or inhibitors for the treatment of cancer and other diseases
WO2022213062A1 (en) 2021-03-29 2022-10-06 Nimbus Saturn, Inc. Hpk1 antagonists and uses thereof
US20240376224A1 (en) 2021-04-02 2024-11-14 The Regents Of The University Of California Antibodies against cleaved cdcp1 and uses thereof
CA3214240A1 (en) 2021-04-05 2022-10-13 Godwin Kwame KUMI Pyridinyl substituted oxoisoindoline compounds for the treatment of cancer
PT4320112T (pt) 2021-04-06 2025-07-07 Bristol Myers Squibb Co Compostos de oxoisoindolina substituĂ­dos por piridinilo
KR20240007155A (ko) 2021-04-09 2024-01-16 님ëČ„ìŠ€ íŽëŠŹì˜€, ìžìœ”íŹë ˆìŽí‹°ë“œ Cbl-b ìĄ°ì ˆì œ 및 읎의 용도
JP2024514879A (ja) 2021-04-16 2024-04-03 ă‚€ă‚±ăƒŠ ă‚Șăƒłă‚łăƒ­ă‚žăƒŒïŒŒ ă‚€ăƒłă‚łăƒŒăƒăƒŹă‚€ăƒ†ăƒƒăƒ‰ ïŒ­ïœ…ïœ‹é˜»ćźłć‰€ćŠăłăăźäœżç”š
AU2022271290A1 (en) 2021-05-07 2023-11-23 Kymera Therapeutics, Inc. Cdk2 degraders and uses thereof
EP4370523A1 (en) 2021-07-14 2024-05-22 Blueprint Medicines Corporation Heterocyclic compounds as map4k1 inhibitors
TW202321238A (zh) 2021-07-15 2023-06-01 çŸŽć•†çșœćœ–è—„擁慬揾 ïŒ­ïœïœïŒ”ïœ‹ïŒ‘æŠ‘ćˆ¶ćŠ‘
JP2024534127A (ja) 2021-08-25 2024-09-18 ピク ă‚»ăƒ©ăƒ”ăƒ„ăƒŒăƒ†ă‚Łă‚Żă‚č ă‚€ăƒłă‚łăƒŒăƒăƒŹă‚€ăƒ†ăƒƒăƒ‰ ïœ…ïŒ©ïŒŠïŒ”ïŒ„é˜»ćźłć‰€ćŠăłăăźäœżç”š
EP4392421A1 (en) 2021-08-25 2024-07-03 PIC Therapeutics, Inc. Eif4e inhibitors and uses thereof
WO2023076556A1 (en) 2021-10-29 2023-05-04 Kymera Therapeutics, Inc. Irak4 degraders and synthesis thereof
WO2023114984A1 (en) 2021-12-17 2023-06-22 Ikena Oncology, Inc. Tead inhibitors and uses thereof
WO2023122777A1 (en) 2021-12-22 2023-06-29 Gossamer Bio Services, Inc. Oxime derivatives useful as t cell activators
WO2023122772A1 (en) 2021-12-22 2023-06-29 Gossamer Bio Services, Inc. Oxime derivatives useful as t cell activators
WO2023122778A1 (en) 2021-12-22 2023-06-29 Gossamer Bio Services, Inc. Pyridazinone derivatives useful as t cell activators
IL314437A (en) 2022-01-31 2024-09-01 Kymera Therapeutics Inc IRAK joints and their uses
EP4472963A1 (en) 2022-02-01 2024-12-11 Arvinas Operations, Inc. Dgk targeting compounds and uses thereof
WO2023173053A1 (en) 2022-03-10 2023-09-14 Ikena Oncology, Inc. Mek inhibitors and uses thereof
WO2023173057A1 (en) 2022-03-10 2023-09-14 Ikena Oncology, Inc. Mek inhibitors and uses thereof
WO2023211889A1 (en) 2022-04-25 2023-11-02 Ikena Oncology, Inc. Polymorphic compounds and uses thereof
WO2023230205A1 (en) 2022-05-25 2023-11-30 Ikena Oncology, Inc. Mek inhibitors and uses thereof
IL318577A (en) 2022-08-02 2025-03-01 Liminal Biosciences Ltd ARYL-TRIAZOLYL AND RELATED GPR84 ANTAGONISTS AND THEIR USES
TW202416950A (zh) 2022-08-02 2024-05-01 è‹±ć•†ćˆ©ç±łé‚Łç”Ÿç‰©ç§‘æŠ€æœ‰é™ć…Źćž é›œèŠłćŸșç”Č醯èƒș揊盾關gpr84æ‹źæŠ—ćŠ‘ćŠć…¶ç”šé€”
JP2025527248A (ja) 2022-08-02 2025-08-20 ăƒȘăƒŸăƒŠăƒ«ăƒ»ăƒă‚€ă‚Șă‚”ă‚€ă‚šăƒłă‚·ăƒŒă‚ș・ăƒȘミテッド çœźæ›ăƒ”ăƒȘăƒ‰ăƒłïœ‡ïœïœ’ïŒ˜ïŒ”ă‚ąăƒłă‚żă‚Žăƒ‹ă‚čăƒˆćŠăłăăźäœżç”š
EP4568950A1 (en) 2022-08-08 2025-06-18 Bristol-Myers Squibb Company Substituted tetrazolyl compounds useful as t cell activators
EP4568963A1 (en) 2022-08-09 2025-06-18 Bristol-Myers Squibb Company Tertiary amine substituted bicyclic compounds useful as t cell activators
AR130167A1 (es) 2022-08-11 2024-11-13 Hoffmann La Roche Derivados bicĂ­clicos de tetrahidroazepina
JP2025526727A (ja) 2022-08-11 2025-08-15 ă‚šăƒ•ăƒ»ăƒ›ăƒ•ăƒžăƒłïŒăƒ©ăƒ»ăƒ­ă‚·ăƒ„ăƒ»ă‚ąă‚Żăƒă‚§ăƒłă‚Čă‚Œăƒ«ă‚·ăƒŁăƒ•ăƒˆ äșŒç’°ćŒăƒ†ăƒˆăƒ©ăƒ’ăƒ‰ăƒ­ăƒă‚ąă‚Œăƒ”ăƒłèȘ˜ć°Žäœ“
JP2025526683A (ja) 2022-08-11 2025-08-15 ă‚šăƒ•ăƒ»ăƒ›ăƒ•ăƒžăƒłïŒăƒ©ăƒ»ăƒ­ă‚·ăƒ„ăƒ»ă‚ąă‚Żăƒă‚§ăƒłă‚Čă‚Œăƒ«ă‚·ăƒŁăƒ•ăƒˆ äșŒç’°ćŒăƒ†ăƒˆăƒ©ăƒ’ăƒ‰ăƒ­ăƒă‚ąă‚Œăƒ”ăƒłèȘ˜ć°Žäœ“
CA3262845A1 (en) 2022-08-11 2024-02-15 F. Hoffmann-La Roche Ag BICYCLIC TETRAHYDROTHIAZEPINE DERIVATIVES
WO2024112894A1 (en) 2022-11-22 2024-05-30 PIC Therapeutics, Inc. Eif4e inhibitors and uses thereof
CN116143726B (zh) * 2022-12-02 2024-09-06 ćčżć·žćž‚è”ç‘žćˆ¶èŻæœ‰é™ć…Źćž äž€ç§çŽŻçŁ·è…șè‹·æ‚èŽšçš„ćˆ¶ć€‡æ–čæł•
WO2024137865A1 (en) 2022-12-22 2024-06-27 Gossamer Bio Services, Inc. Compounds useful as t cell activators
AU2024267385A1 (en) 2023-05-08 2026-01-08 Bristol-Myers Squibb Company Substituted phenyl oxazolone compounds
TW202509014A (zh) 2023-05-10 2025-03-01 çŸŽć•†çșœćœ–è—„擁慬揾 ïŒ§ïŒłïŒ«ïŒ“Î±æŠ‘ćˆ¶ćŠ‘ćŠć…¶äœżç”šæ–čæł•
WO2024249540A1 (en) 2023-05-31 2024-12-05 Bristol-Myers Squibb Company Substituted oxazolone compound for decreasing levels of ikzf1-4 proteins
WO2024254227A1 (en) 2023-06-07 2024-12-12 Bristol-Myers Squibb Company Spirocyclic substituted oxoisoindolinyl piperidine-2,6-dione compound
WO2024263853A1 (en) 2023-06-23 2024-12-26 Bristol-Myers Squibb Company Substituted oxoisoindolinyl piperidine-2,6-dione compound as anticancer agent
WO2024264017A2 (en) 2023-06-23 2024-12-26 Kymera Therapeutics, Inc. Irak degraders and uses thereof
WO2025030002A2 (en) 2023-08-02 2025-02-06 Arvinas Operations, Inc. Dgk targeting compounds and uses thereof
WO2025064197A1 (en) 2023-09-02 2025-03-27 Bristol-Myers Squibb Company Substituted azetidinyl oxoisoindolinyl piperidine-2,6-dione compounds
EP4568957A1 (en) 2023-09-02 2025-06-18 Bristol-Myers Squibb Company Substituted phenyl oxooxazolyl piperidine dione compounds
WO2025059245A1 (en) 2023-09-13 2025-03-20 Bristol-Myers Squibb Company Substituted oxoisoindolinyl piperidine-2,6-dione compounds
WO2025096487A1 (en) 2023-10-31 2025-05-08 Bristol-Myers Squibb Company Ubiquitin specific processing protease 1 (usp1) compounds
WO2025096489A1 (en) 2023-10-31 2025-05-08 Bristol-Myers Squibb Company Ubiquitin specific processing protease 1 (usp1) compounds
WO2025096490A1 (en) 2023-10-31 2025-05-08 Bristol-Myers Squibb Company Ubiquitin specific processing protease 1 (usp1) compounds
WO2025096505A1 (en) 2023-10-31 2025-05-08 Bristol-Myers Squibb Company Ubiquitin specific processing protease 1 (usp1) compounds
WO2025096494A1 (en) 2023-10-31 2025-05-08 Bristol-Myers Squibb Company Ubiquitin specific processing protease 1 (usp1) compounds
WO2025096488A1 (en) 2023-10-31 2025-05-08 Bristol-Myers Squibb Company Ubiquitin specific processing protease 1 (usp1) compounds
WO2025096539A1 (en) 2023-10-31 2025-05-08 Bristol-Myers Squibb Company Ubiquitin specific processing protease 1 (usp1) compounds
WO2025226767A1 (en) 2024-04-24 2025-10-30 Bristol-Myers Squibb Company Substituted 3-(5-(6-aminopyridin-2-yl)-4-fluoro-1-oxoisoindolin-2-yl)piperidine-2,6-dione compounds for use in the treatment of cancer
CN119707950A (zh) * 2024-12-24 2025-03-28 æ— é”Ąćž‚ć—äșŹć€§ć­Šé”Ąć±±ćș”ç”šç”Ÿç‰©æŠ€æœŻç ”ç©¶æ‰€ 侀种甹äșŽć…ç–«è›‹ç™œé¶ć‘é™è§Łçš„ć”Œćˆäœ“ćŠć…¶ćˆ¶ć€‡æ–čæł•ć’Œćș”甚

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0126713B1 (de) 1983-05-18 1989-01-18 Ciba-Geigy Ag Cyclohexandion-carbonsÀurederivate mit herbizider und das Pflanzenwachstum regulierender Wirkung
US5807892A (en) 1994-09-30 1998-09-15 Alcon Laboratories, Inc. Use of certain prostaglandin analogues to treat glaucoma and ocular hypertension
US6451840B1 (en) 1997-12-05 2002-09-17 Medical College Of Georgia Research Institute, Inc. Regulation of T cell-mediated immunity by tryptophan
WO2003087347A1 (en) 2002-04-12 2003-10-23 Medical College Of Georgia Research Institute, Inc. Antigen-presenting cell populations and their use as reagents for enhancing or reducing immune tolerance
JP4921965B2 (ja) 2003-03-27 2012-04-25 ăƒ©ăƒłă‚±ăƒŠăƒŒ ă‚€ăƒłă‚čăƒ†ă‚Łăƒ†ăƒ„ăƒŒăƒˆ ăƒ•ă‚©ăƒŒ ăƒĄăƒ‡ă‚Łă‚«ăƒ« ăƒȘă‚”ăƒŒăƒ 癌æČ»ç™‚æ–°èŠæ–čćŒ
US7598287B2 (en) 2003-04-01 2009-10-06 Medical College Of Georgia Research Institute, Inc. Use of inhibitors of indoleamine-2,3-dioxygenase in combination with other therapeutic modalities
JP2007520559A (ja) 2004-02-03 2007-07-26 ă‚ąăƒœăƒƒăƒˆăƒ»ăƒ©ăƒœăƒ©ăƒˆăƒȘăƒŒă‚ș æČ»ç™‚è–Źăšă—ăŠăźă‚ąăƒŸăƒŽăƒ™ăƒłă‚Ÿă‚Șă‚­ă‚”ă‚ŸăƒŒăƒ«éĄž
WO2006122150A1 (en) 2005-05-10 2006-11-16 Incyte Corporation Modulators of indoleamine 2,3-dioxygenase and methods of using the same
US7705022B2 (en) 2005-10-27 2010-04-27 Lankenau Institute For Medical Research IDO inhibitors and methods of use thereof
CA2634198C (en) 2005-12-20 2014-06-03 Incyte Corporation N-hydroxyamidinoheterocycles as modulators of indoleamine 2,3-dioxygenase
US8389568B2 (en) 2007-03-16 2013-03-05 Lankenau Institute For Medical Research IDO inhibitors and methods of use thereof
DE102007020493A1 (de) 2007-04-30 2008-11-06 GrĂŒnenthal GmbH Substituierte Amid-Derivate
JP5583592B2 (ja) * 2007-11-30 2014-09-03 ăƒ‹ăƒ„ăƒŒăƒȘンク ゾェネティクă‚č ă‚łăƒŒăƒăƒŹă‚€ă‚·ăƒ§ăƒł ïŒ©ïœ„ïœé˜»ćźłć‰€
MX2010006457A (es) 2007-12-19 2010-07-05 Amgen Inc Compuestos fusionados de piridina, pirimidina y triazina como inhibidores de ciclo celular.
CN102083429B (zh) * 2008-04-24 2014-05-28 新联ćŸș曠慬揾 IdoæŠ‘ćˆ¶ć‰‚
KR101847107B1 (ko) 2008-07-08 2018-04-10 ìžì‚ŹìŽíŠž 홀딩슀 ìœ”íŹë ˆìŽì…˜ ìžëŒì•„ëŻŒ ,-디옄시êČŒë‚˜ì•„ì œì˜ ì–”ì œì œëĄœì„œì˜ ,,-ì˜„ì‚Źë””ì•„ìĄž
EP2493862B1 (en) 2009-10-28 2016-10-05 Newlink Genetics Corporation Imidazole derivatives as ido inhibitors
NO2694640T3 (Direct) * 2011-04-15 2018-03-17
EP2922847A1 (en) 2012-11-20 2015-09-30 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of indoleamine 2,3-dioxygenase
WO2014141110A2 (en) 2013-03-14 2014-09-18 Curadev Pharma Pvt. Ltd. Aminonitriles as kynurenine pathway inhibitors
MX2015012028A (es) 2013-03-14 2016-02-11 Curadev Pharma Private Ltd Inhibidores de la ruta de quinurenina.
RU2667509C2 (ru) 2013-03-14 2018-09-21 ĐŃŒŃŽĐ»ĐžĐœĐș Đ”Đ¶ĐžĐœĐ”Ń‚ĐžĐșс ĐšĐŸŃ€ĐżĐŸŃ€Đ”ĐčŃˆĐžĐœ броцоĐșлОчДсĐșОД ŃĐŸĐ”ĐŽĐžĐœĐ”ĐœĐžŃ ĐČ ĐșачДстĐČĐ” ĐžĐœĐłĐžĐ±ĐžŃ‚ĐŸŃ€ĐŸĐČ ĐžĐŒĐŒŃƒĐœĐŸŃŃƒĐżŃ€Đ”ŃŃĐžĐž, ĐŸĐżĐŸŃŃ€Đ”ĐŽŃƒĐ”ĐŒĐŸĐč ĐŒĐ”Ń‚Đ°Đ±ĐŸĐ»ĐžĐ·ĐžŃ€ĐŸĐČĐ°ĐœĐžĐ”ĐŒ Ń‚Ń€ĐžĐżŃ‚ĐŸŃ„Đ°ĐœĐ°
HRP20180971T1 (hr) 2013-03-15 2018-08-10 Bristol-Myers Squibb Company Inhibitori indolamin 2,3-dioksigenaze (ido)
HK1220442A1 (zh) 2013-03-15 2017-05-05 Bristol-Myers Squibb Company IdoæŠ‘ćˆ¶ć‰‚
CN105473550B (zh) 2013-07-01 2019-02-15 ç™Ÿæ—¶çŸŽæ–œèŽ”ćźć…Źćž IdoæŠ‘ćˆ¶ć‰‚
CA2917964A1 (en) 2013-07-11 2015-01-15 Bristol-Myers Squibb Company Ido inhibitors

Also Published As

Publication number Publication date
EP3018132A1 (en) 2016-05-11
RU2017107026A3 (Direct) 2019-01-23
KR20140059167A (ko) 2014-05-15
MX340442B (es) 2016-07-08
RU2613579C2 (ru) 2017-03-17
US9260434B2 (en) 2016-02-16
IL241846A (en) 2016-06-30
PT3018132T (pt) 2018-03-09
HRP20180335T1 (hr) 2018-04-20
CA2833296C (en) 2020-12-08
JP5837673B2 (ja) 2015-12-24
NO2694640T3 (Direct) 2018-03-17
US20180118753A1 (en) 2018-05-03
AU2012242871A1 (en) 2013-10-31
EP3348558A1 (en) 2018-07-18
EP2697227A1 (en) 2014-02-19
HUE038586T2 (hu) 2018-10-29
HK1256355A1 (en) 2019-09-20
JP6145491B2 (ja) 2017-06-14
PL3018132T3 (pl) 2018-05-30
AU2018202706A1 (en) 2018-05-10
IL228862A (en) 2015-10-29
KR102164443B1 (ko) 2020-10-12
RS54723B1 (sr) 2016-08-31
AU2012242871B2 (en) 2014-09-11
JP2014511876A (ja) 2014-05-19
CA2833296A1 (en) 2012-10-18
US20160362412A1 (en) 2016-12-15
CN105111210A (zh) 2015-12-02
JP2017149769A (ja) 2017-08-31
PL2697227T3 (pl) 2016-09-30
SMT201600130B (it) 2016-07-01
US10233190B2 (en) 2019-03-19
AU2014274564A1 (en) 2015-01-22
AU2012242871A8 (en) 2013-11-21
AU2012242871C1 (en) 2017-02-02
PE20141124A1 (es) 2014-09-06
HK1193822A1 (zh) 2014-10-03
PE20181023A1 (es) 2018-06-27
IL241846A0 (en) 2015-11-30
HK1223371A1 (en) 2017-07-28
US9850248B2 (en) 2017-12-26
LT3018132T (lt) 2018-03-26
AU2014274564B2 (en) 2016-10-06
AU2016277574B2 (en) 2018-04-19
EP3018132B1 (en) 2017-12-13
RS56992B1 (sr) 2018-05-31
NZ723271A (en) 2018-03-23
IL228862A0 (en) 2013-12-31
SI3018132T1 (en) 2018-04-30
JP2016029092A (ja) 2016-03-03
US9388191B2 (en) 2016-07-12
HRP20160369T1 (hr) 2016-06-03
DK2697227T3 (en) 2016-04-25
HUE027316T2 (en) 2016-10-28
CL2013002990A1 (es) 2014-07-04
US20140066625A1 (en) 2014-03-06
IL246515B (en) 2018-08-30
US20190225618A1 (en) 2019-07-25
CN103547579B (zh) 2017-02-15
DK3018132T3 (en) 2018-03-12
EP2697227B1 (en) 2016-02-03
CO6862146A2 (es) 2014-02-10
RU2013150811A (ru) 2015-05-20
US20160002249A1 (en) 2016-01-07
CY1117440T1 (el) 2017-04-26
NZ616457A (en) 2015-05-29
JP2015061877A (ja) 2015-04-02
RU2017107026A (ru) 2019-01-23
WO2012142237A8 (en) 2012-11-22
ES2569665T3 (es) 2016-05-12
AU2016277574A1 (en) 2017-01-12
CN103547579A (zh) 2014-01-29
SI2697227T1 (sl) 2016-06-30
WO2012142237A1 (en) 2012-10-18
NZ708090A (en) 2016-12-23
CN105111210B (zh) 2018-10-09
ES2660831T3 (es) 2018-03-26
BR112013026494A2 (pt) 2016-12-27
MX2013012021A (es) 2014-07-10

Similar Documents

Publication Publication Date Title
IL246515B (en) Imidazole derivatives are designed for use as ido inhibitors
ZA201303801B (en) Fused aminodihydrothiazine derivatives useful as bace inhibitors
ZA201305612B (en) Pyrrolotriazinone derivatives as pi3k inhibitors
SG10201601802YA (en) Dispiropyrrolidine derivatives
IL233366A0 (en) Tetra or penta pyridophthalazinones are conjugated as parp inhibitors
IL227252A0 (en) Aminodihydrothiazine history from sisterhood
ZA201305826B (en) Substituted amminobutyric derivatives as neprilysin inhibitors
IL228949A0 (en) History of pyrazolospiroctone for use as acetyl-CoA carboxylase inhibitors
IL233365A0 (en) Tetra or pentacyclic dihydrodiazepinocarbazolones are conjugated as parp inhibitors
IL258704B (en) History of hydantoins used as kv3 inhibitors
AP3529A (en) Hydroxymethylaryl-substituted pyrrolotriazines as alk1 inhibitors
IL247639B (en) History of heteroaryl piperidine
IL229990A0 (en) History of n-oxypyrazolo-triazapine-dione
EP2744788A4 (en) BENZOPIPERAZINE DERIVATIVES AS CETP INHIBITORS
EP2703403A4 (en) imidazole
SI2766342T1 (sl) Derivati fenil-gvanidina
ZA201308049B (en) 3-ureidoisoquinolin-8-yl derivatives
PT2721009E (pt) Derivados de pirazole Ășteis como inibidores de aldosterona sintase
HK1186463A (en) Fused aminodihydrothiazine derivatives useful as bace inhibitors
ZA201209319B (en) Cyclopropyl-indole derivatives
ZA201308697B (en) Hydroxymethylaryl-substituted pyprolotriazines as alk1 inhibitors
GB201120474D0 (en) Inhibitors
GB201100183D0 (en) Fused aminodihydropyrimidone derivatives